Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep 1;85(9):1347–1350. doi: 10.1054/bjoc.2001.2103

Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients

G H de Bock 1, R A E M Tollenaar 2, H Papelard 1, C J Cornelisse 3, P Devilee 3,4, M J van de Vijver 3
PMCID: PMC2375234  PMID: 11720473

Abstract

Thus far, studies investigating the differences in tumour characteristics between breast cancer in BRCA1-carriers and other patients, have focused on highly selected groups of patients, potentially limiting the conclusions that can be drawn. Previously, we had identified 10 patients with BRCA1 germline mutations in a hospital-based series of 642 breast cancer patients not selected for age or family history. The aim of this analysis is to investigate the clinical and pathological features of these BRCA1 associated carcinomas as compared to other breast cancers in this representative sample. Tumours from patients with BRCA1 germline mutations (n= 10) were compared to an age-matched sample of other patients (n= 50) from the same cohort. The following characteristics were considered: axillary nodal status and tumour size, histologic parameters (tumour type, histologic grade, mitotic rate, tubule formation, nuclear grade, CIS and lymphangio invasion) and expression of several proteins (oestrogen and progesterone receptors, cyclin D1, p53, HER2/neu, E-cadherin). In BRCA1associated tumours receptors for oestrogen and progesterone were expressed less frequently (respectively P= 0.001 and P= 0.002) than in controls, which is in line with findings from other studies. Other differences were also in accordance with findings from other studies, although not statistically significant. We conclude that the features of BRCA1 associated tumours detected in a hospital-based series of breast cancer patients not selected for family history of age at diagnosis are similar to tumours in cases selected for family history or age at diagnosis. © 2001 Cancer Research Campaign  http://www.bjcancer.com

Keywords: breast neoplasms, BRCA1 gene, population study, histology

Full Text

The Full Text of this article is available as a PDF (68.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armes J. E., Egan A. J., Southey M. C., Dite G. S., McCredie M. R., Giles G. G., Hopper J. L., Venter D. J. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998 Dec 1;83(11):2335–2345. [PubMed] [Google Scholar]
  2. Armes J. E., Trute L., White D., Southey M. C., Hammet F., Tesoriero A., Hutchins A. M., Dite G. S., McCredie M. R., Giles G. G. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999 Apr 15;59(8):2011–2017. [PubMed] [Google Scholar]
  3. Brown D. L., Cole B. F., Arrick B. A. Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1999 Jan 6;91(1):90–91. doi: 10.1093/jnci/91.1.90a. [DOI] [PubMed] [Google Scholar]
  4. Cattoretti G., Pileri S., Parravicini C., Becker M. H., Poggi S., Bifulco C., Key G., D'Amato L., Sabattini E., Feudale E. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol. 1993 Oct;171(2):83–98. doi: 10.1002/path.1711710205. [DOI] [PubMed] [Google Scholar]
  5. Crook T., Crossland S., Crompton M. R., Osin P., Gusterson B. A. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 1997 Aug 30;350(9078):638–639. doi: 10.1016/S0140-6736(05)63327-2. [DOI] [PubMed] [Google Scholar]
  6. Eisinger F., Jacquemier J., Charafe-Jauffret E., Rio M. C., Birnbaum D., Sobol H. More about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1999 Aug 18;91(16):1421–1422. doi: 10.1093/jnci/91.16.1421. [DOI] [PubMed] [Google Scholar]
  7. Eisinger F., Stoppa-Lyonnet D., Longy M., Kerangueven F., Noguchi T., Bailly C., Vincent-Salomon A., Jacquemier J., Birnbaum D., Sobol H. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996 Feb 1;56(3):471–474. [PubMed] [Google Scholar]
  8. Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403–410. doi: 10.1111/j.1365-2559.1991.tb00229.x. [DOI] [PubMed] [Google Scholar]
  9. Jacquemier J., Eisinger F., Noguès C., Sun Z. Z., Guinebretière J. M., Peyrat J. P., Geneix J., Lidereau R., Birnbaum D., Sobol H. Histological type and syncytial growth pattern affect E-cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1-associated breast cancers. Int J Cancer. 1999 Sep 24;83(1):45–49. doi: 10.1002/(sici)1097-0215(19990924)83:1<45::aid-ijc9>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  10. Jóhannsson O. T., Idvall I., Anderson C., Borg A., Barkardóttir R. B., Egilsson V., Olsson H. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997 Mar;33(3):362–371. doi: 10.1016/s0959-8049(97)89007-7. [DOI] [PubMed] [Google Scholar]
  11. Karp S. E., Tonin P. N., Bégin L. R., Martinez J. J., Zhang J. C., Pollak M. N., Foulkes W. D. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997 Aug 1;80(3):435–441. doi: 10.1002/(sici)1097-0142(19970801)80:3<435::aid-cncr11>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  12. Lakhani S. R., Jacquemier J., Sloane J. P., Gusterson B. A., Anderson T. J., van de Vijver M. J., Farid L. M., Venter D., Antoniou A., Storfer-Isser A. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998 Aug 5;90(15):1138–1145. doi: 10.1093/jnci/90.15.1138. [DOI] [PubMed] [Google Scholar]
  13. Lidereau R., Eisinger F., Champème M. H., Noguès C., Bièche I., Birnbaum D., Pallud C., Jacquemier J., Sobol H. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 2000 Mar 1;60(5):1206–1210. [PubMed] [Google Scholar]
  14. Loman N., Johannsson O., Bendahl P. O., Borg A., Fernö M., Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998 Jul 15;83(2):310–319. [PubMed] [Google Scholar]
  15. Lynch B. J., Holden J. A., Buys S. S., Neuhausen S. L., Gaffney D. K. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol. 1998 Oct;29(10):1140–1144. doi: 10.1016/s0046-8177(98)90427-0. [DOI] [PubMed] [Google Scholar]
  16. Marcus J. N., Watson P., Page D. L., Narod S. A., Lenoir G. M., Tonin P., Linder-Stephenson L., Salerno G., Conway T. A., Lynch H. T. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996 Feb 15;77(4):697–709. doi: 10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  17. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Papelard H., de Bock G. H., van Eijk R., Vliet Vlieland T. P., Cornelisse C. J., Devilee P., Tollenaar R. A. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer. 2000 Sep;83(6):719–724. doi: 10.1054/bjoc.2000.1331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997 May 24;349(9064):1505–1510. [PubMed] [Google Scholar]
  20. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov;17(3):341–345. doi: 10.1038/ng1197-341. [DOI] [PubMed] [Google Scholar]
  21. Phillips K. A., Andrulis I. L., Goodwin P. J. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol. 1999 Nov;17(11):3653–3663. doi: 10.1200/JCO.1999.17.11.3653. [DOI] [PubMed] [Google Scholar]
  22. Phillips K. A., Nichol K., Ozcelik H., Knight J., Done S. J., Goodwin P. J., Andrulis I. L. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst. 1999 Mar 3;91(5):469–473. doi: 10.1093/jnci/91.5.469. [DOI] [PubMed] [Google Scholar]
  23. Robson M., Gilewski T., Haas B., Levin D., Borgen P., Rajan P., Hirschaut Y., Pressman P., Rosen P. P., Lesser M. L. BRCA-associated breast cancer in young women. J Clin Oncol. 1998 May;16(5):1642–1649. doi: 10.1200/JCO.1998.16.5.1642. [DOI] [PubMed] [Google Scholar]
  24. Shuber A. P., Grondin V. J., Klinger K. W. A simplified procedure for developing multiplex PCRs. Genome Res. 1995 Dec;5(5):488–493. doi: 10.1101/gr.5.5.488. [DOI] [PubMed] [Google Scholar]
  25. Verhoog L. C., Brekelmans C. T., Seynaeve C., van den Bosch L. M., Dahmen G., van Geel A. N., Tilanus-Linthorst M. M., Bartels C. C., Wagner A., van den Ouweland A. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998 Jan 31;351(9099):316–321. doi: 10.1016/s0140-6736(97)07065-7. [DOI] [PubMed] [Google Scholar]
  26. van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES